HALB Archives - Page 3 of 6 - Halberd Corporation

May 17 2021

Halberd Corporation Reports Successful Conjugation of Metallic Particles & SARS-CoV-2 Proprietary Monoclonal Antibody

By Admin|2021-05-17T11:12:47-04:00May 17th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, May 17, 2021 – Halberd Corporation (OTC-PINK: "HALB") announces the successful conjugation of gold-coated iron nanoparticles with Halberd’s patent-pending monoclonal antibody against the SARS-CoV-2 spike protein. This milestone paves the way for testing to proceed on the elimination of disease through the application of extracorporeal radio frequency waves or laser emissive energy ...

May 13 2021

Halberd Corporation Begins Testing of Patented Process for Laser Eradication of Disease

By Admin|2021-05-12T20:19:30-04:00May 13th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, May 13, 2021 – Halberd Corporation (OTC-PINK: "HALB") announces the commencement of its patented extra-corporeal process experimentation using lasers to eradicate disease. This technology facilitates disease eradication without the side-effects normally associated with conventional internal medications. The experimentation is now being conducted at Youngstown State University (YSU) under the direct supervision of ...

May 10 2021

Halberd Corp. Designated as a BREAKOUT Stock to Watch in Investor Publications

By Admin|2021-05-09T20:41:34-04:00May 10th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, May 10, 2021 – Halberd Corporation (OTC-PINK: "HALB") was recently discussed in Penny Stocks News and Wall Street Trader publications as a BREAKOUT stock to watch with a projected share price of HALB to rise above the $0.06/share level. Halberd Corporation did not participate in these determinations, nor does it subscribe thereto, ...

May 4 2021

Halberd Corporation Appoints New Chief Technical Officer to Optimize Upcoming Experiments On Radio Frequency and Laser Eradication of Disease

By Admin|2021-05-04T07:46:18-04:00May 4th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, May 4, 2021 – Halberd Corporation (OTC-PINK: "HALB") announces the appointment of Dr. Mitchell S. Felder, previously a consultant to Halberd Corporation, to the position of Chief Technical Officer. Dr. Patricio Reyes, former Chief Technical Officer, has requested reduced duties due to pressing other outside commitments, but will continue to serve as ...

Apr 26 2021

Halberd Corporation Files International Patent Cooperation Treaty (PCT) Application on Treating and Curing Covid-19 Infection Utilizing a Laser

By Admin|2021-04-25T23:01:11-04:00April 26th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, April 26, 2021 – Halberd Corporation (OTC-PINK: "HALB") filed an International Patent Cooperation Treaty (PCT) application for coverage of the invention titled, “Treating and Curing Covid-19 Infection Utilizing a Laser.” The Patent Cooperation Treaty has over 150 participating countries and allows an inventor to seek patent protection in numerous countries simultaneously. William ...

Apr 19 2021

Halberd Corporation Moves Radio Frequency (RF) Disease Elimination Effort Forward With the Addition of Youngstown State University (YSU) and Dr. William G. Sturrus

By Admin|2021-04-18T21:39:58-04:00April 19th, 2021|Featured, Investor News, News, Uncategorized|0 Comments

Brings Critical Radio Frequency Wave Expertise to Company’s Effort Jackson Center, PA, April 19, 2021 – Halberd Corporation (OTC-PINK: "HALB") is pleased to announce Youngstown State University’s (YSU) Dr. William G. Sturrus will lead the Radio Frequency (RF) research on Halberd’s Disease Elimination multi-organization Task Force. Dr. Sturrus, who has 30 years of radio ...

Apr 12 2021

Halberd Corporation Files International Patent Cooperation Treaty (PCT) Application on Covid-19 Inflammatory Cytokine Storm Treatment

By Admin|2021-04-11T20:02:28-04:00April 12th, 2021|Featured, Investor News, News, Uncategorized|0 Comments

Jackson Center, PA, April 12, 2021 – Halberd Corporation (OTC-PINK: "HALB") filed an International Patent Cooperation Treaty (PCT) application for coverage of the invention titled, “Covid-19 Inflammatory Cytokine Storm Treatment.” The Patent Cooperation Treaty has over 150 participating countries and allows an inventor to seek patent protection in numerous countries simultaneously. William A. Hartman, Chairman, ...

Apr 6 2021

Halberd Corporation CEO Letter

By Admin|2021-04-05T20:46:11-04:00April 6th, 2021|Featured, Investor News, News|0 Comments

Q1-21 Accomplishments and Q2 Plans Jackson Center, PA, April 6, 2021 Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC-PINK: HALB) It has been a very busy and fruitful first quarter of 2021. Often, people get so wrapped up in the day-to-day events that we lose sight of just how far we have traveled. ...

Feb 16 2021

Halberd Collaborates With GreenBioAZ, Inc. For the Development of Its Patent Pending Radio Frequency Technology to Eliminate Disease Pathogens

By Admin|2021-02-15T21:23:39-05:00February 16th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, February 16, 2021 – Halberd Corp. (OTC PINK:HALB) has engaged GreenBioAZ, Inc. to conduct laboratory testing of Halberd’s patent pending Radio Frequency (RF) extracorporeal treatment to eliminate infectious disease pathogens. The methodology entails treating bodily fluids with an Antibody-Metallic Moiety Conjugate (AMMC) which targets a specific pathogen such as SARS-CoV-2 during extracorporeally ...

Jan 14 2021

Halberd Corp. Develops Medication to Boost Immune System Against SARS-CoV-2 (Covid-19)

By Admin|2021-01-13T18:47:16-05:00January 14th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, January 14, 2021 – Halberd Corp. (OTC PINK: "HALB") announced the filing of a provisional patent application on a proprietary combination of nutritional supplements (melatonin, zinc and Vitamin D) combined with low dose Naltrexone designed to reduce the severity of Covid-19 symptoms. This proprietary combination of nutritional supplements is based on numerous ...

Previous 234 Next